← Leaderboards
Mayer Fishman
H. Lee Moffitt Cancer Ctr & Res Inst
$458,562
Attributed
$458,562
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $264.8K · FY2008–09$500K$375K$250K$125K$0
'08
'09
Funding mix
By agency
FDA$458,562 · 1
By mechanism
R01$458,562 · 1
Top collaborators
No co-investigators on record.
Grant awards (3)
Phase I Study of ALT-801 in Metastatic Melanoma/Kidney Cancer Patients$201,603
R01 · FY2009 · FD · contact PI
Phase I Study of ALT-801 in Metastatic Melanoma/Kidney Cancer Patients$63,244
R01 · FY2009 · FD · contact PI
Phase I Study of ALT-801 in Metastatic Melanoma/Kidney Cancer Patients$193,715
R01 · FY2008 · FD · contact PI